Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Jonathan K Reynolds
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c03116aca28d4503b4a56a3c00a08e98
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c03116aca28d4503b4a56a3c00a08e98
record_format	dspace
spelling	oai:doaj.org-article:c03116aca28d4503b4a56a3c00a08e982021-12-02T00:49:44ZFixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes1178-7007https://doaj.org/article/c03116aca28d4503b4a56a3c00a08e982009-07-01T00:00:00Zhttp://www.dovepress.com/fixed-dose-combination-of-sitagliptin-and-metformin-for-the-treatment--a3384https://doaj.org/toc/1178-7007Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form. Sitagliptin, an inhibitor of the enzyme DDP-4, assists patients with type 2 diabetes mellitus to achieve glycemic control. It has been shown to be safe and effective at 100 mg daily doses. The effect of giving sitagliptin in combination with metformin is thought to have a complimentary and possibly additive effect on glycemic control.Keywords: sitagliptin, metformin, fixed-dose combination, dipeptidyl peptidase-4 inhibitor, DPP-4 inhibitor Jonathan K ReynoldsDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 127-134 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Jonathan K Reynolds Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
description	Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form. Sitagliptin, an inhibitor of the enzyme DDP-4, assists patients with type 2 diabetes mellitus to achieve glycemic control. It has been shown to be safe and effective at 100 mg daily doses. The effect of giving sitagliptin in combination with metformin is thought to have a complimentary and possibly additive effect on glycemic control.Keywords: sitagliptin, metformin, fixed-dose combination, dipeptidyl peptidase-4 inhibitor, DPP-4 inhibitor
format	article
author	Jonathan K Reynolds
author_facet	Jonathan K Reynolds
author_sort	Jonathan K Reynolds
title	Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
title_short	Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
title_full	Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
title_fullStr	Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
title_full_unstemmed	Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
title_sort	fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/c03116aca28d4503b4a56a3c00a08e98
work_keys_str_mv	AT jonathankreynolds fixeddosecombinationofsitagliptinandmetforminforthetreatmentoftype2diabetes
_version_	1718403463848656896

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

Ejemplares similares